Drugs / Encepur
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT00840801 | Feb 2009 → May 2010 | tick-borne encephalitis | Pfizer | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT00387634 Comparator | Sep 2006 → Oct 2011 | tick-borne encephalitis | Novartis Vaccines | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Encepur | “The aim of this study was thus to evaluate the long-term persistence of TBE antibodies in adults and adolescents after a first booster dose with Encepur(®).” PMID 24950352 ↗ Jun 20141“Subjects receive two vaccinations with Encepur 0.25ml Children on days 0 and 28 and a third vaccination with FSME-IMMUN 0.25ml Junior on day 360.” NCT00840801 ↗ |